Evidence map›Paper›PMID 25673560›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2015

Prevalence and Incidence of Respiratory Syncytial Virus and Other Respiratory Viral Infections in Children Aged 6 Months to 10 Years With Influenza-like Illness Enrolled in a Randomized Trial.

Terry Nolan, Charissa Borja-Tabora, Pio Lopez, Lily Weckx, Rolando Ulloa-Gutierrez, Eduardo Lazcano-Ponce, Angkool Kerdpanich, Miguel Angel Rodriguez Weber, Abiel Mascareñas de Los Santos, Juan-Carlos Tinoco and 12 more

Registry-linked trialAbstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01051661 (A Study to Evaluate the Safety and Efficacy of A/California/7/2009), which is not on this map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01051661 phase3completednot on this map

A Study to Evaluate the Safety and Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children Aged 6 Months to Less Than 10 Years of Age

TypeinterventionalSponsorGlaxoSmithKlineRan2010 to 2011Enrolled6,154ConditionsInfluenzaArmsGSK Biologicals' investigational vaccine GSK2340274A (alternative formulations), GSK Biologicals' investigational vaccine GSK2340273A (alternative formulations), Placebo
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Incidence and seasonality of respiratory syncytial virus hospitalisations in young children in Denmark, 2010 to 2015.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2018
    Article
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Article
  18. Metagenomic analysis of viral genetic diversity in respiratory samples from children with severe acute respiratory infection in China.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2016
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Terry NolanMurdoch Children's Research Institute and Melbourne School of Population and Global Health, University of Melbourne, Carlton, Victoria, Australia.
Charissa Borja-TaboraDepartment of Health, Research Institute for Tropical Medicine, Alabang, Muntinlupa City, Philippines.
Pio LopezCentro de Estudios en Infectologia Pediatrica, Cali, Colombia.
Lily WeckxPediatric Infectious Diseases, Department of Pediatrics, Universidade Federal de São Paulo, Brazil.
Rolando Ulloa-GutierrezInstituto Costarricense de Investigaciones Clínicas, San José, Costa Rica.
Eduardo Lazcano-PonceNational Institute of Public Health of Mexico, Cuernavaca Morelos.
Angkool KerdpanichInfectious Diseases Unit, Department of Pediatrics, Phramongkutklao Hospital, Thailand.
Miguel Angel Rodriguez WeberInstituto Nacional de Pediatría de Mexico.
Abiel Mascareñas de Los SantosServicios Medicos Universidad Autonoma de Nuevo Leon, Monterrey.
Juan-Carlos TinocoHospital General de Durango, Mexico.
Marco Aurelio P SafadiDepartment of Pediatrics, Faculdade de Ciências Médicas da Santa Casa de São Paulo and Associação Fundo de Incentivo à Pesquisa, Brazil.
Lim Fong SengNational Healthcare Group Polyclinics, Singapore.
Marcela Hernandez-de MezervilleInstituto Costarricense de Investigaciones Clínicas, San José, Costa Rica.
Idis FaingezichtInstituto Costarricense de Investigaciones Clínicas, San José, Costa Rica.
Aurelio Cruz-ValdezNational Institute of Public Health of Mexico, Cuernavaca Morelos.
Yang FengGSK Vaccines, Wavre, Belgium.
Ping LiGSK Vaccines, King of Prussia, Pennsylvania.
Serge DurviauxGSK Vaccines, Wavre, Belgium.
Gerco HaarsGSK Vaccines, Wavre, Belgium.
Sumita Roy-GhantaGSK Vaccines, King of Prussia, Pennsylvania.
David W VaughnGSK Vaccines, Rixensart, Belgium.
Sylvia TaylorGSK Vaccines, Wavre, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe high burden of respiratory syncytial virus (RSV)-associated morbidity and mortality makes vaccine development a priority.

methodsAs part of an efficacy trial of pandemic influenza vaccines (NCT01051661), RSV epidemiology in healthy children aged 6 months to <10 years at first vaccination with influenza-like illness (ILI) was evaluated in Australia, Brazil, Colombia, Costa Rica, Mexico, the Philippines, Singapore, and Thailand between February 2010 and August 2011. Active surveillance for ILI was conducted for approximately 1 year, with nasal and throat swabs analyzed by polymerase chain reaction. The prevalence and incidence of RSV among ILI episodes were calculated.

resultsA total of 6266 children were included, of whom 2421 experienced 3717 ILI episodes with a respiratory sample available. RSV was detected for 359 ILI episodes, a prevalence of 9.7% (95% confidence interval: 8.7-10.7). The highest prevalence was in children aged 12-23 or 24-35 months in all countries except the Philippines, where it was in children aged 6-11 months. The incidence of RSV-associated ILI was 7.0 (6.3-7.7) per 100 person-years (PY). Eighty-eight ILI episodes resulted in hospitalization, of which 8 were associated with RSV (prevalence 9.1% [4.0-17.1]; incidence 0.2 [0.1-0.3] per 100 PY). The incidence of RSV-associated ILI resulting in medical attendance was 6.0 (5.4-6.7) per 100 PY. RSV B subtypes were observed more frequently than A subtypes.

conclusionsActive surveillance demonstrated the considerable burden of RSV-associated illness that would not be identified through hospital-based surveillance, with a substantial part of the burden occurring in older infants and children.

Indexed as

Respiratory Syncytial VirusesRespiratory Syncytial Virus InfectionsChildChild, PreschoolFemaleHumansIncidenceInfantMaleNasal MucosaPharynxPolymerase Chain ReactionPrevalenceRandomized Controlled Trials as TopicchildrenILIincidenceprevalenceRSV

Identifiers

PMID25673560
PMCPMC4429758

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.